Search results
J&J’s Tremfya superior to Stelara in Phase II/III Chron’s disease trials
Clinical Trials Arena via Yahoo Finance· 4 days agoJohnson and Johnson’s Johnson and Johnson’s Tremfya (guselkumab) was superior to its Stelara...
Lilly (LLY) Hits Record High on Crohn's Disease Study Data
Zacks via Yahoo Finance· 3 days agoHowever, the results were mixed when the results when the Lilly drug was pitted against J&J’s JNJ...
IBD Stock Of The Day Eli Lilly Breaks Out On Its Way To A Record High
Investor's Business Daily· 4 days agoIn the patients who worsened while taking a prior biologic, 43.4% of mirikizumab patients entered...
J&J’s Tremfya meets endpoints in Phase III ulcerative colitis trial
Clinical Trials Arena via Yahoo Finance· 5 days agoJ&J’s Tremfya is expected to be the successor to the company’s IL-12/IL-23 inhibitor Stelara...
Finding the Best Psoriasis Treatment: How I Got Psoriasis Relief
Verywell Health via Yahoo News· 4 days agoLiving Life With Psoriasis As with many chronic illnesses, psoriasis cannot be cured, but it can be...
Johnson & Johnson shares maintain outperform rating at RBC on TREMFYA potential By Investing.com
Investing.com· 4 days agoOn Wednesday, RBC (TSX:RY) Capital maintained its positive stance on Johnson & Johnson (NYSE:JNJ),...
Alvotech (NYSE:ALVO) Releases Quarterly Earnings Results, Misses Estimates By $0.81 EPS
ETF DAILY NEWS· 2 days agoAlvotech (NYSE:ALVO – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates ...
Guselkumab Continues Winning Streak in Crohn's Disease
MedPage Today· 4 days agoInduction and maintenance treatment with guselkumab (Tremfya) demonstrated its safety and efficacy...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 4 days agoTotal revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year. Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last year. Alvotech signed new commercialization
Earnings call: Alvotech raises 2024 guidance amid strong biosimilar push By Investing.com
Investing.com· 3 days agoAlvotech, a global biopharmaceutical company, has reported a robust first quarter in 2024, with...